Joshua M. Eizen - Jan 3, 2025 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Operating Officer and Chief Legal Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen
Stock symbol
ANTX
Transactions as of
Jan 3, 2025
Transactions value $
-$12,958
Form type
4
Date filed
1/7/2025, 07:57 PM
Previous filing
Nov 5, 2024
Next filing
Feb 28, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Sale -$13K -9.66K -7.65% $1.34 117K Jan 3, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2025.
F2 Includes (a) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 (b) 22,500 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025 and (c) 45,000 RSUs which vest as follows: 2/3rd of the RSU vest on January 1, 2026 and 1/3rd of the RSUs vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date.

Remarks:

Chief Operating Officer and Chief Legal Officer